arrow
N

Najla El Jurdi

Center for International Blood and Marrow Transplant Research
H指数:14
被引数:1,175

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical risk factors alone do not predict the development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation and post-transplant cyclophosphamide

仅临床风险因素无法预测造血细胞移植及移植后环磷酰胺治疗中中重度慢性移植物抗宿主病的发展

2026-10-290
PRE
Membranous Conjunctivitis in Acute and Chronic Graft-Versus-Host Disease: Longitudinal Ocular Outcomes

膜性结膜炎在急性与慢性移植物抗宿主病中的纵向眼部结局

2026-10-220
OAAI
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant

移植物抗宿主病预防措施塑造造血细胞移植后的T细胞生物学和免疫重建

2026-10-210
PRE
Mitochondrial genetic variation as a novel predictor of graft-versus-host disease after stem-cell transplantation in myelodysplastic neoplasms

骨髓增生异常肿瘤干细胞移植后移植物抗宿主病的新的预测因子——线粒体遗传变异

2026-10-010
OAAI
Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target

硬化性慢性移植物抗宿主病中升高的血浆大麻素水平突显内源性大麻素系统作为潜在的治疗靶点

2026-08-080
PRE
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

巴瑞替尼治疗难治性慢性移植物抗宿主病:一项1/2期研究的结果

2026-05-280
OAAI
Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study

通过抗阻训练减轻高强度癌症治疗后免疫衰老标志物的减弱:一项试点研究

Cancers
IF4.4
2026-05-240
OA
Frailty is associated with low physical activity and poor sleep quality in patients undergoing myeloablative allogeneic hematopoietic cell transplantation: a Fitbit® pilot study

虚弱与接受骨髓清除性异基因造血细胞移植患者的低身体活动量和睡眠质量差相关:一项Fitbit®初步研究

2025-12-080
OAAI
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377

勘误表:Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532;文章编号:JTCT-S-25-00377

2025-10-070
PRE
Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

选择HLA错配无亲缘关系供体与单倍型相同供体:供体年龄的考量

2025-05-240
PRE
Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT

I期/II期高剂量palifermin用于HLA匹配无关供者HCT患者GVHD预防的研究

Blood
IF23.1
2025-05-090
PRE
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

基于移植后环磷酰胺的GVHD预防在70岁及以上患者中的影响:BMT CTN 1703的更新

2025-05-050
OA